{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:21:06Z","timestamp":1792016466768,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222048"],"award-info":[{"award-number":["82222048"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173338"],"award-info":[{"award-number":["82173338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67262-x","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:26:44Z","timestamp":1765819604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PD-1\/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Liang","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanxu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyou","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanze","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8617-8886","authenticated-orcid":false,"given":"Gao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"67262_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour, K. C. & Riely, G. J. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA 322, 764\u2013774 (2019).","journal-title":"JAMA"},{"key":"67262_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"67262_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon, D. et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell 42, 209\u2013224 e209 (2024).","journal-title":"Cancer Cell"},{"key":"67262_CR4","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","volume":"20","author":"SJ Antonia","year":"2019","unstructured":"Antonia, S. J. et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 20, 1395\u20131408 (2019).","journal-title":"Lancet Oncol."},{"key":"67262_CR5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","volume":"32","author":"AJ Schoenfeld","year":"2021","unstructured":"Schoenfeld, A. J. et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann. Oncol. 32, 1597\u20131607 (2021).","journal-title":"Ann. Oncol."},{"key":"67262_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.lungcan.2023.02.002","volume":"178","author":"E Auclin","year":"2023","unstructured":"Auclin, E. et al. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. Lung Cancer 178, 116\u2013122 (2023).","journal-title":"Lung Cancer"},{"key":"67262_CR7","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.jtho.2022.07.043","volume":"17","author":"E Auclin","year":"2022","unstructured":"Auclin, E. et al. OA07.06 second line treatment outcomes after progression on immunotherapy plus chemotherapy (IO-CT) in advanced non-small cell lung cancer (aNSCLC). J. Thorac. Oncol. 17, S22 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"67262_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","volume":"13","author":"SE Park","year":"2018","unstructured":"Park, S. E. et al. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer. J. Thorac. Oncol. 13, 106\u2013111 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"67262_CR9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Yang, H., Chon, H. J. & Kim, C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 52, 1475\u20131485 (2020).","journal-title":"Exp. Mol. Med."},{"key":"67262_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao, S. et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol. Res 7, 630\u2013643 (2019).","journal-title":"Cancer Immunol. Res"},{"key":"67262_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta, K. et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71, 1247\u20131261 (2020).","journal-title":"Hepatology"},{"key":"67262_CR12","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00262-021-02869-9","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunol. Immunother. 70, 2517\u20132528 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"67262_CR13","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1200\/JCO.23.02166","volume":"42","author":"J Neal","year":"2024","unstructured":"Neal, J. et al. CONTACT-01: a randomized phase III trial of atezolizumab + cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy. J. Clin. Oncol. 42, 2393\u20132403 (2024).","journal-title":"J. Clin. Oncol."},{"key":"67262_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","volume":"35","author":"H Borghaei","year":"2024","unstructured":"Borghaei, H. et al. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Ann. Oncol. 35, 66\u201376 (2024).","journal-title":"Ann. Oncol."},{"key":"67262_CR15","doi-asserted-by":"crossref","unstructured":"Leighl, N. B. et al. LEAP-008: lenvatinib plus pembrolizumab for metastatic NSCLC that has progressed after an anti PD-(L)1 plus platinum chemotherapy. J. Thorac. Oncol. 20, 1489\u20131504.","DOI":"10.1016\/j.jtho.2025.05.020"},{"key":"67262_CR16","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp, K. L. et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J. Clin. Oncol. 40, 2295\u20132306 (2022).","journal-title":"J. Clin. Oncol."},{"key":"67262_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong, A. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet 405, 839\u2013849 (2025).","journal-title":"Lancet"},{"key":"67262_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01562-5","volume":"22","author":"T Li","year":"2024","unstructured":"Li, T., Niu, M., Zhou, J., Wu, K. & Yi, M. The enhanced antitumor activity of bispecific antibody targeting PD-1\/PD-L1 signaling. Cell Commun. Signal 22, 179 (2024).","journal-title":"Cell Commun. Signal"},{"key":"67262_CR19","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1158\/2326-6066.CIR-20-0304","volume":"8","author":"H Kotanides","year":"2020","unstructured":"Kotanides, H. et al. Bispecific targeting of PD-1 and PD-L1 enhances T-cell activation and antitumor immunity. Cancer Immunol. Res. 8, 1300\u20131310 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"67262_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290\u2013296 (2015).","journal-title":"Immunol. Cell Biol."},{"key":"67262_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","volume":"4","author":"RE Kontermann","year":"2012","unstructured":"Kontermann, R. E. Dual targeting strategies with bispecific antibodies. MAbs 4, 182\u2013197 (2012).","journal-title":"MAbs"},{"key":"67262_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"67262_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01761-7","volume":"22","author":"R Ruan","year":"2023","unstructured":"Ruan, R. et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment. Mol. Cancer 22, 60 (2023).","journal-title":"Mol. Cancer"},{"key":"67262_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","volume":"22","author":"CH Lee","year":"2021","unstructured":"Lee, C. H. et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): a phase 1b\/2 study. Lancet Oncol. 22, 946\u2013958 (2021).","journal-title":"Lancet Oncol."},{"key":"67262_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield, L. H. & Najjar, Y. G. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat. Rev. Immunol. 24, 399\u2013416 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"67262_CR26","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight 6, e150735 (2021).","DOI":"10.1172\/jci.insight.150735"},{"key":"67262_CR27","doi-asserted-by":"crossref","unstructured":"Geindreau, M., Ghiringhelli, F. & Bruchard, M. Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int. J. Mol. Sci. 22, e150735 (2021).","DOI":"10.3390\/ijms22094871"},{"key":"67262_CR28","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jtho.2022.07.201","volume":"17","author":"M Reck","year":"2022","unstructured":"Reck, M. et al. P1.15-05 nintedanib in combination with Nivolumab in pretreated patients with advanced adenocarcinoma of the lung (AIO-TRK-0117 Phase IB\/II Trial). J. Thorac. Oncol. 17, S121 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"67262_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jtho.2023.02.016","volume":"18","author":"K He","year":"2023","unstructured":"He, K. et al. MRTX-500 phase 2 trial: sitravatinib with nivolumab in patients with nonsquamous NSCLC progressing on or after checkpoint inhibitor therapy or chemotherapy. J. Thorac. Oncol. 18, 907\u2013921 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"67262_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-024-01644-4","volume":"17","author":"DY Ruan","year":"2024","unstructured":"Ruan, D. Y. et al. The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia\/Ib study. J. Hematol. Oncol. 17, 118 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"67262_CR31","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor, M. H. et al. Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J. Clin. Oncol. 38, 1154\u20131163 (2020).","journal-title":"J. Clin. Oncol."},{"key":"67262_CR32","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/JCO.21.00939","volume":"39","author":"SK Pal","year":"2021","unstructured":"Pal, S. K. et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study. J. Clin. Oncol. 39, 3725\u20133736 (2021).","journal-title":"J. Clin. Oncol."},{"key":"67262_CR33","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.19.02627","volume":"38","author":"V Makker","year":"2020","unstructured":"Makker, V. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J. Clin. Oncol. 38, 2981\u20132992 (2020).","journal-title":"J. Clin. Oncol."},{"key":"67262_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.22.00221","volume":"41","author":"A Arance","year":"2023","unstructured":"Arance, A. et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J. Clin. Oncol. 41, 75\u201385 (2023).","journal-title":"J. Clin. Oncol."},{"key":"67262_CR35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano, L., Jordao, M. J. C. & Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 11, 933\u2013959 (2021).","journal-title":"Cancer Discov."},{"key":"67262_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin, M. Z. & Jin, W. L. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct. Target Ther. 5, 166 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"67262_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer 21, 28 (2022).","journal-title":"Mol. Cancer"},{"key":"67262_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"67262_CR39","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J. Clin. Investig. 128, 4654\u20134668 (2018).","journal-title":"J. Clin. Investig."},{"key":"67262_CR40","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade. Nat. Cancer 3, 1123\u20131136 (2022).","journal-title":"Nat. Cancer"},{"key":"67262_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"67262_CR42","doi-asserted-by":"crossref","unstructured":"Baumjohann, D. & Brossart, P. T Follicular helper cells: linking cancer immunotherapy and immune-related adverse events. J. Immunother. Cancer9, e002588 (2021).","DOI":"10.1136\/jitc-2021-002588"},{"key":"67262_CR43","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","volume":"179","author":"DP Hollern","year":"2019","unstructured":"Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191\u20131206 e1121 (2019).","journal-title":"Cell"},{"key":"67262_CR44","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Alonso, S., et al. A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. J. Immunother. Cancer 8, e001187 (2020).","DOI":"10.1136\/jitc-2020-001187"},{"key":"67262_CR45","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593 e1578 (2021).","journal-title":"Cancer Cell"},{"key":"67262_CR46","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell 42, 1268\u20131285.e1267 (2024).","journal-title":"Cancer Cell"},{"key":"67262_CR47","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt, J. M. et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and extrinsic factors. Immunity 44, 1255\u20131269 (2016).","journal-title":"Immunity"},{"key":"67262_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen, B. H., Ali, B. R. & Elkord, E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol. Cancer 24, 20 (2025).","journal-title":"Mol. Cancer"},{"key":"67262_CR49","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1093\/nar\/gky1173","volume":"47","author":"B Dura","year":"2019","unstructured":"Dura, B. et al. scFTD-seq: freeze-thaw lysis-based, portable approach toward highly distributed single-cell 3\u2019 mRNA profiling. Nucleic Acids Res. 47, e16 (2019).","journal-title":"Nucleic Acids Res."},{"key":"67262_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"67262_CR51","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"67262_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"67262_CR53","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn, L. et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, Phase III trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35, 3924\u20133933 (2017).","journal-title":"J. Clin. Oncol."},{"key":"67262_CR54","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang, S. et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 53, D1670\u2013d1676 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67262-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67262-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67262-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:04:58Z","timestamp":1768489498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67262-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67262"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67262-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.Z. is employed by Innovent Biologics (Suzhou) Co., Ltd. The other authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"567"}}